Study Summary:
Individuals with colorectal cancer that has metastasized (spread) are invited to inquire about participation in a clinical research study. This study will evaluate an investigational fully human monoclonal antibody combined with chemotherapy to see if it will extend survival for a longer period of time, compared to the best available standard of care regimen. Monoclonal antibodies are substances produced in a laboratory that can locate and bind to cancer cells by recognizing specific substances on cancer cells. These antibodies are used to find and attack tumors.
Qualified Participants Must:
• Have unresectable (inoperable) colorectal cancer that has metastasized (spread)
•
Be at least 18 years of age
•
Not have received a prior treatment regimen for their advanced-stage colorectal cancer
•
Meet other enrollment criteria
Qualified Participants May Receive:
Study-related medication and study-related procedures at no cost